Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

Sattar N., Preiss D., Robinson JG., Djedjos CS., Elliott M., Somaratne R., Wasserman SM., Raal FJ.

DOI

10.1016/S2213-8587(16)00003-6

Type

Journal article

Journal

The Lancet Diabetes & Endocrinology

Publication Date

02/2016

Permalink Original publication